Alzheimer’s is a progressive disorder which leads to wasting off the brain cells and is one of the most common causes of dementia. The first set of symptoms includes a decline in thinking, behavioural and social skills and disruption in the body’s ability to function start to appear between 40 and 65 years of age.
As per the National Center for Chronic Disease Prevention and Health Promotion, “In 2014, an estimated 5 million Americans aged 65 years or older had Alzheimer’s disease. This number is projected to nearly triple to 14 million people by 2060”.
The key players in the Alzheimer’s disease market at a global level include Neurotrope bioscience, Amarantus Bioscience Holdings, AgeneBio, Novartis, Cortexyme, TauRx Therapeutics, Otsuka Pharmaceutical, AC Immune, Genentech, Alkahest, AZ Therapies, and others.
For more information visit:
https://www.delveinsight.com/blog/alzheimers-disease-market-trend/